taxonomy (1)
protein (1)
source (4)
structure (10)
composition (119)
disease (2)
reference (5)
site (6)
peptide (7)
- Homo sapiens (Human)
Taxonomy
- Mammary Gland (UBERON_0001911)
- Ovary (UBERON_0000992) CHO (CVCL_0213)
- Umbilical Vein (UBERON_0002066) Endothelial Cell of Umbilical Vein (CL_0002618)
- Urine (UBERON_0001088)
Source
- N-Linked / Complex / GlcNAc(b1-2)Man(a1-3)[GlcNAc(b1-2)Man(a1-6)]Man(b1-4)GlcNAc(b1-4)GlcNAc
- N-Linked / Complex / Gal(b1-4)GlcNAc(b1-2)Man(a1-?)[GlcNAc(b1-2)Man(a1-?)]Man(b1-4)GlcNAc(b1-4)[Fuc(a1-6)]GlcNAc
- N-Linked / Complex / Gal(b1-4)GlcNAc(b1-2)Man(a1-3)[Gal(b1-4)GlcNAc(b1-2)Man(a1-6)]Man(b1-4)GlcNAc(b1-4)GlcNAc
- N-Linked / Complex / Gal(b1-4)GlcNAc(b1-2)Man(a1-3)[Gal(b1-4)GlcNAc(b1-2)Man(a1-6)]Man(b1-4)GlcNAc(b1-4)[Fuc(a1-6)]GlcNAc
- N-Linked / Complex / NeuAc(a2-?)Gal(b1-4)GlcNAc(b1-2)Man(a1-?)[Gal(b1-4)GlcNAc(b1-2)Man(a1-?)]Man(b1-4)GlcNAc(b1-4)GlcNAc
- N-Linked / Complex / NeuAc(a2-?)Gal(b1-4)GlcNAc(b1-2)Man(a1-?)[Gal(b1-4)GlcNAc(b1-2)Man(a1-?)]Man(b1-4)GlcNAc(b1-4)[Fuc(a1-6)]GlcNAc
- N-Linked / Complex / Gal(b1-4)GlcNAc(b1-3)Gal(b1-4)GlcNAc(b1-2)Man(a1-?)[Gal(b1-4)GlcNAc(b1-2)Man(a1-?)]Man(b1-4)GlcNAc(b1-4)[Fuc(a1-6)]GlcNAc
- N-Linked / Complex / Gal(b1-4)GlcNAc(b1-3)Gal(b1-4)GlcNAc(b1-2)Man(a1-?)[Gal(b1-4)GlcNAc(b1-2)Man(a1-?)]Man(b1-4)GlcNAc(b1-4)[Fuc(a1-6)]GlcNAc+"+ Gal(b1-4)GlcNAc(b1-3)"
- N-Linked / Complex / Gal(b1-4)GlcNAc(b1-3)Gal(b1-4)GlcNAc(b1-2)Man(a1-?)[Gal(b1-4)GlcNAc(b1-2)Man(a1-?)]Man(b1-4)GlcNAc(b1-4)[Fuc(a1-6)]GlcNAc+"+ 2 x Gal(b1-4)GlcNAc(b1-3)"
- N-Linked / Complex / Gal(b1-4)GlcNAc(b1-3)Gal(b1-4)GlcNAc(b1-2)Man(a1-?)[Gal(b1-4)GlcNAc(b1-2)Man(a1-?)]Man(b1-4)GlcNAc(b1-4)[Fuc(a1-6)]GlcNAc+"+ 3 x Gal(b1-4)GlcNAc(b1-3)"
Reported structure
- HexNAc:3 dHex:1 (avg mass : 773.7433 )
- Hex:1 HexNAc:1 NeuAc:3 (avg mass : 1257.1264 )
- Hex:1 HexNAc:2 dHex:1 NeuAc:1 (avg mass : 1023.9486 )
- Hex:1 HexNAc:3 (avg mass : 789.7427 )
- Hex:1 HexNAc:3 dHex:1 (avg mass : 935.8857 )
- Hex:1 HexNAc:4 (avg mass : 992.9377 )
- Hex:1 HexNAc:4 dHex:1 (avg mass : 1139.0807 )
- Hex:2 HexNAc:2 (avg mass : 748.6901 )
- Hex:2 HexNAc:2 dHex:1 (avg mass : 894.8331 )
- Hex:2 HexNAc:2 dHex:1 NeuAc:1 (avg mass : 1186.091 )
- Hex:2 HexNAc:3 dHex:1 (avg mass : 1098.0281 )
- Hex:2 HexNAc:4 (avg mass : 1155.0801 )
- Hex:2 HexNAc:4 dHex:2 (avg mass : 1447.3661 )
- Hex:3 HexNAc:2 dHex:1 (avg mass : 1056.9755 )
- Hex:3 HexNAc:4 (avg mass : 1317.2225 )
- Hex:3 HexNAc:4 dHex:2 (avg mass : 1609.5085 )
- Hex:3 HexNAc:6 dHex:1 NeuAc:1 NeuGc:1 (avg mass : 2468.2707 )
- Hex:3 HexNAc:9 dHex:1 (avg mass : 2479.3405 )
- Hex:4 HexNAc:4 NeuGc:1 (avg mass : 1786.6222 )
- Hex:4 HexNAc:4 dHex:1 (avg mass : 1625.5079 )
- Hex:4 HexNAc:4 dHex:1 NeuAc:1 (avg mass : 1916.7658 )
- Hex:4 HexNAc:4 dHex:3 (avg mass : 1917.7939 )
- Hex:4 HexNAc:5 NeuAc:1 (avg mass : 1973.8178 )
- Hex:4 HexNAc:5 dHex:1 (avg mass : 1828.7029 )
- Hex:4 HexNAc:5 dHex:1 NeuAc:1 (avg mass : 2119.9608 )
- Hex:4 HexNAc:5 dHex:1 NeuAc:1 NeuGc:1 (avg mass : 2427.2181 )
- Hex:4 HexNAc:5 dHex:1 NeuAc:2 (avg mass : 2411.2187 )
- Hex:4 HexNAc:5 dHex:2 NeuAc:1 (avg mass : 2266.1038 )
- Hex:4 HexNAc:7 dHex:2 (avg mass : 2381.2359 )
- Hex:4 HexNAc:9 dHex:1 (avg mass : 2641.4829 )
- Hex:5 HexNAc:3 dHex:3 (avg mass : 1876.7413 )
- Hex:5 HexNAc:4 (avg mass : 1641.5073 )
- Hex:5 HexNAc:4 NeuAc:1 (avg mass : 1932.7652 )
- Hex:5 HexNAc:4 NeuAc:2 (avg mass : 2224.0231 )
- Hex:5 HexNAc:4 dHex:1 (avg mass : 1787.6503 )
- Hex:5 HexNAc:4 dHex:1 NeuGc:2 (avg mass : 2402.1649 )
- Hex:5 HexNAc:4 dHex:1 NeuAc:1 (avg mass : 2078.9082 )
- Hex:5 HexNAc:4 dHex:1 NeuAc:1 NeuGc:1 (avg mass : 2386.1655 )
- Hex:5 HexNAc:4 dHex:1 NeuAc:2 (avg mass : 2370.1661 )
- Hex:5 HexNAc:4 dHex:2 (avg mass : 1933.7933 )
- Hex:5 HexNAc:4 dHex:2 NeuAc:1 (avg mass : 2225.0512 )
- Hex:5 HexNAc:4 dHex:3 NeuGc:2 (avg mass : 2694.4509 )
- Hex:5 HexNAc:4 dHex:3 NeuAc:1 (avg mass : 2371.1942 )
- Hex:5 HexNAc:4 dHex:3 NeuAc:1 NeuGc:1 (avg mass : 2678.4515 )
- Hex:5 HexNAc:4 dHex:3 NeuAc:2 (avg mass : 2662.4521 )
- Hex:5 HexNAc:4 dHex:4 (avg mass : 2226.0793 )
- Hex:5 HexNAc:5 (avg mass : 1844.7023 )
- Hex:5 HexNAc:5 NeuAc:1 (avg mass : 2135.9602 )
- Hex:5 HexNAc:5 dHex:1 (avg mass : 1990.8453 )
- Hex:5 HexNAc:5 dHex:1 NeuAc:1 (avg mass : 2282.1032 )
- Hex:5 HexNAc:5 dHex:1 NeuAc:2 (avg mass : 2573.3611 )
- Hex:5 HexNAc:5 dHex:2 (avg mass : 2136.9883 )
- Hex:5 HexNAc:5 dHex:2 NeuAc:1 (avg mass : 2428.2462 )
- Hex:5 HexNAc:5 dHex:3 (avg mass : 2283.1313 )
- Hex:5 HexNAc:6 dHex:1 NeuGc:3 (avg mass : 3115.8122 )
- Hex:5 HexNAc:6 dHex:1 NeuAc:1 (avg mass : 2485.2982 )
- Hex:5 HexNAc:6 dHex:3 (avg mass : 2486.3263 )
- Hex:5 HexNAc:8 dHex:1 (avg mass : 2600.4303 )
- Hex:6 HexNAc:3 dHex:3 (avg mass : 2038.8837 )
- Hex:6 HexNAc:4 (avg mass : 1803.6497 )
- Hex:6 HexNAc:4 NeuAc:1 (avg mass : 2094.9076 )
- Hex:6 HexNAc:4 dHex:1 (avg mass : 1949.7927 )
- Hex:6 HexNAc:4 dHex:1 NeuAc:1 (avg mass : 2241.0506 )
- Hex:6 HexNAc:4 dHex:2 (avg mass : 2095.9357 )
- Hex:6 HexNAc:4 dHex:3 (avg mass : 2242.0787 )
- Hex:6 HexNAc:5 NeuAc:1 (avg mass : 2298.1026 )
- Hex:6 HexNAc:5 NeuAc:2 NeuGc:1 (avg mass : 2896.6178 )
- Hex:6 HexNAc:5 NeuAc:3 (avg mass : 2880.6184 )
- Hex:6 HexNAc:5 dHex:1 (avg mass : 2152.9877 )
- Hex:6 HexNAc:5 dHex:1 NeuGc:1 (avg mass : 2460.245 )
- Hex:6 HexNAc:5 dHex:1 NeuGc:2 (avg mass : 2767.5023 )
- Hex:6 HexNAc:5 dHex:1 NeuAc:1 (avg mass : 2444.2456 )
- Hex:6 HexNAc:5 dHex:1 NeuAc:1 NeuGc:1 (avg mass : 2751.5029 )
- Hex:6 HexNAc:5 dHex:1 NeuAc:1 NeuGc:2 (avg mass : 3058.7602 )
- Hex:6 HexNAc:5 dHex:1 NeuAc:2 (avg mass : 2735.5035 )
- Hex:6 HexNAc:5 dHex:1 NeuAc:2 NeuGc:1 (avg mass : 3042.7608 )
- Hex:6 HexNAc:5 dHex:1 NeuAc:3 (avg mass : 3026.7614 )
- Hex:6 HexNAc:5 dHex:2 NeuAc:1 (avg mass : 2590.3886 )
- Hex:6 HexNAc:5 dHex:3 NeuGc:1 (avg mass : 2752.531 )
- Hex:6 HexNAc:5 dHex:3 NeuAc:1 (avg mass : 2736.5316 )
- Hex:6 HexNAc:6 NeuAc:1 (avg mass : 2501.2976 )
- Hex:6 HexNAc:6 NeuAc:1 NeuGc:1 (avg mass : 2808.5549 )
- Hex:6 HexNAc:6 dHex:1 NeuAc:1 (avg mass : 2647.4406 )
- Hex:6 HexNAc:6 dHex:1 NeuAc:1 NeuGc:1 (avg mass : 2954.6979 )
- Hex:6 HexNAc:6 dHex:1 NeuAc:2 (avg mass : 2938.6985 )
- Hex:6 HexNAc:6 dHex:2 (avg mass : 2502.3257 )
- Hex:6 HexNAc:7 (avg mass : 2413.2347 )
- Hex:6 HexNAc:8 (avg mass : 2616.4297 )
- Hex:7 HexNAc:4 NeuAc:1 (avg mass : 2257.05 )
- Hex:7 HexNAc:4 dHex:1 (avg mass : 2111.9351 )
- Hex:7 HexNAc:4 dHex:2 (avg mass : 2258.0781 )
- Hex:7 HexNAc:5 dHex:1 (avg mass : 2315.1301 )
- Hex:7 HexNAc:5 dHex:1 NeuAc:1 (avg mass : 2606.388 )
- Hex:7 HexNAc:5 dHex:1 NeuAc:1 NeuGc:1 (avg mass : 2913.6453 )
- Hex:7 HexNAc:5 dHex:1 NeuAc:2 (avg mass : 2897.6459 )
- Hex:7 HexNAc:6 (avg mass : 2372.1821 )
- Hex:7 HexNAc:6 NeuGc:1 (avg mass : 2679.4394 )
- Hex:7 HexNAc:6 NeuAc:3 (avg mass : 3245.9558 )
- Hex:7 HexNAc:6 NeuAc:3 NeuGc:1 (avg mass : 3553.2131 )
- Hex:7 HexNAc:6 dHex:1 (avg mass : 2518.3251 )
- Hex:7 HexNAc:6 dHex:1 NeuAc:1 (avg mass : 2809.583 )
- Hex:7 HexNAc:6 dHex:1 NeuAc:2 (avg mass : 3100.8409 )
- Hex:7 HexNAc:6 dHex:1 NeuAc:3 (avg mass : 3392.0988 )
- Hex:7 HexNAc:6 dHex:4 NeuAc:1 (avg mass : 3248.012 )
- Hex:7 HexNAc:7 dHex:1 (avg mass : 2721.5201 )
- Hex:7 HexNAc:8 (avg mass : 2778.5721 )
- Hex:8 HexNAc:2 (avg mass : 1721.5445 )
- Hex:8 HexNAc:6 dHex:1 NeuAc:1 (avg mass : 2971.7254 )
- Hex:8 HexNAc:7 NeuAc:1 (avg mass : 3028.7774 )
- Hex:8 HexNAc:7 dHex:1 (avg mass : 2883.6625 )
- Hex:8 HexNAc:7 dHex:1 NeuAc:1 (avg mass : 3174.9204 )
- Hex:8 HexNAc:7 dHex:1 NeuAc:2 (avg mass : 3466.1783 )
- Hex:9 HexNAc:6 (avg mass : 2696.4669 )
- Hex:9 HexNAc:8 NeuAc:1 (avg mass : 3394.1148 )
- Hex:9 HexNAc:8 dHex:1 (avg mass : 3248.9999 )
- Hex:10 HexNAc:2 (avg mass : 2045.8293 )
- Hex:10 HexNAc:6 dHex:1 NeuAc:1 (avg mass : 3296.0102 )
- Hex:10 HexNAc:9 dHex:1 (avg mass : 3614.3373 )
- Hex:12 HexNAc:2 (avg mass : 2370.1141 )
Composition
- Distinct urinary glycoprotein signatures in prostate cancer patients (2018 - Rebeca Kawahara, Fabio Ortega, Livia Rosa-Fernandes, Vanessa Guimarães, Daniel Quina, Willian Nahas, Veit Schwämmle, Miguel Srougi, Katia R.M. Leite, Morten Thaysen-Andersen, Martin R. Larsen and Giuseppe Palmisano) / Status : Unreviewed
- Reanalysis of global proteomic and phosphoproteomic data identified a large number of glycopeptides (2018 - Yingwei Hu, Punit Shah, David J. Clark, Minghui Ao, Hui Zhang) / Status : Unreviewed
- Glycoproteomic analysis of the secretome of human endothelial cells (2013 - Yin X, Bern M, Xing Q, Ho J, Viner R, Mayr M.) / Status : Reviewed
- Oligosaccharide analysis and molecular modeling of soluble forms of glycoproteins belonging to the Ly-6, scavenger receptor, and immunoglobulin superfamilies expressed in Chinese hamster ovary cells. (1999 - Rudd P, Wormald M, Harvey D, Devasahayam M, McAlister M, Brown M, Davis S, Barclay A, Dwek R) / Status : Reviewed
- Structural study on the glycosyl-phosphatidylinositol anchor and the asparagine-linked sugar chain of a soluble form of CD59 in human urine. (1994 - Nakano Y, Noda K, Endo T, Kobata A, Tomita M) / Status : Reviewed
Reference
- CD59 glycoprotein / Homo sapiens
Reported glycosite
- TAVNCSSDFDACLITKAGLQVYNKCWK (27aa)
- TAVNCSSDFDACLITK (16aa)
- TAVNCSSDFDACLITK (16aa)
- TAVNCSSDFDACLITKAGLQVYNK (24aa)
- TAVNCSSDFDACIITK (16aa)
- KDLCNFNEQLENGGTSLSEK (20aa)
- DLCNFNEQLENGGTSLSEK (19aa)
- DLCNFNEQLENGGTSLSEK (19aa)
- DLCNFNEQLENGGTSLSEKTVLLLVTPFLAAAWSLHP (37aa)
- DLCNFNEQLENGGTSLSEKTVLLLVTPFLAAAWSLHP (37aa)
Mass spectrometry observed peptide
-
- N-Linked / Complex (avg mass : 1317.2225)
- Urine (UBERON_0001088)
-
CD59 glycoprotein / Homo sapiens
- Undefined site
-
- N-Linked / Complex (avg mass : 1625.5079)
- Ovary (UBERON_0000992) CHO (CVCL_0213)
-
CD59 glycoprotein / Homo sapiens
- Undefined site
-
- N-Linked / Complex (avg mass : 1641.5073)
- Urine (UBERON_0001088)
-
CD59 glycoprotein / Homo sapiens
- Undefined site
-
- N-Linked / Complex (avg mass : 1787.6503)
- Oligosaccharide analysis and molecular modeling of soluble forms of glycoproteins belonging to the Ly-6, scavenger receptor, and immunoglobulin superfamilies expressed in Chinese hamster ovary cells. (1999 - Rudd P, Wormald M, Harvey D, Devasahayam M, McAlister M, Brown M, Davis S, Barclay A, Dwek R) / Status : Reviewed
- Structural study on the glycosyl-phosphatidylinositol anchor and the asparagine-linked sugar chain of a soluble form of CD59 in human urine. (1994 - Nakano Y, Noda K, Endo T, Kobata A, Tomita M) / Status : Reviewed
-
CD59 glycoprotein / Homo sapiens
- Undefined site
- CD59 glycoprotein / Homo sapiens
-
- N-Linked / Complex (avg mass : 1932.7652)
- Urine (UBERON_0001088)
-
CD59 glycoprotein / Homo sapiens
- Undefined site
- CD59 glycoprotein / Homo sapiens
-
- N-Linked / Complex (avg mass : 2078.9082)
- Urine (UBERON_0001088)
-
CD59 glycoprotein / Homo sapiens
- Undefined site
- CD59 glycoprotein / Homo sapiens
-
- N-Linked / Complex (avg mass : 2152.9877)
- Ovary (UBERON_0000992) CHO (CVCL_0213)
-
CD59 glycoprotein / Homo sapiens
- Undefined site
- CD59 glycoprotein / Homo sapiens
-
- N-Linked / Complex (avg mass : 2518.3251)
- Ovary (UBERON_0000992) CHO (CVCL_0213)
-
CD59 glycoprotein / Homo sapiens
- Undefined site
-
- N-Linked / Complex (avg mass : 2883.6625)
- Ovary (UBERON_0000992) CHO (CVCL_0213)
-
CD59 glycoprotein / Homo sapiens
- Undefined site
-
- N-Linked / Complex (avg mass : 3248.9999)
- Ovary (UBERON_0000992) CHO (CVCL_0213)
-
CD59 glycoprotein / Homo sapiens
- Undefined site
- CD59 glycoprotein / Homo sapiens
-
- Hex:2 HexNAc:2 / N-Linked (avg mass : 748.6901)
- Urine (UBERON_0001088)
- Prostate cancer (DOID:10283)
- CD59 glycoprotein / Homo sapiens
- TAVNCSSDFDACLITK (16aa)
- TAVNCSSDFDACLITK (16aa)
-
- Hex:8 HexNAc:2 / N-Linked (avg mass : 1721.5445)
- Urine (UBERON_0001088)
- Prostate cancer (DOID:10283)
- CD59 glycoprotein / Homo sapiens
- TAVNCSSDFDACLITK (16aa)
- TAVNCSSDFDACLITK (16aa)
-
- Hex:4 HexNAc:4 NeuGc:1 / N-Linked (avg mass : 1786.6222)
- Urine (UBERON_0001088)
- Prostate cancer (DOID:10283)
- CD59 glycoprotein / Homo sapiens
- TAVNCSSDFDACLITK (16aa)
- TAVNCSSDFDACLITK (16aa)
-
- Hex:5 HexNAc:4 dHex:1 / N-Linked (avg mass : 1787.6503)
- Urine (UBERON_0001088)
- Prostate cancer (DOID:10283)
- CD59 glycoprotein / Homo sapiens
- TAVNCSSDFDACLITK (16aa)
- TAVNCSSDFDACLITK (16aa)
-
- Hex:6 HexNAc:4 / N-Linked (avg mass : 1803.6497)
- Urine (UBERON_0001088)
- Prostate cancer (DOID:10283)
- CD59 glycoprotein / Homo sapiens
- TAVNCSSDFDACLITK (16aa)
- TAVNCSSDFDACLITK (16aa)
-
- Hex:4 HexNAc:5 dHex:1 / N-Linked (avg mass : 1828.7029)
- Urine (UBERON_0001088)
- Prostate cancer (DOID:10283)
- CD59 glycoprotein / Homo sapiens
- TAVNCSSDFDACLITK (16aa)
- TAVNCSSDFDACLITK (16aa)
-
- Hex:5 HexNAc:5 / N-Linked (avg mass : 1844.7023)
- Urine (UBERON_0001088)
- Prostate cancer (DOID:10283)
- CD59 glycoprotein / Homo sapiens
- TAVNCSSDFDACLITK (16aa)
- TAVNCSSDFDACLITK (16aa)
-
- Hex:5 HexNAc:3 dHex:3 / N-Linked (avg mass : 1876.7413)
- Mammary Gland (UBERON_0001911)
- Cancer, breast (DOID:1612)
- CD59 glycoprotein / Homo sapiens
- TAVNCSSDFDACIITK (16aa)
-
- Hex:4 HexNAc:4 dHex:1 NeuAc:1 / N-Linked (avg mass : 1916.7658)
- Urine (UBERON_0001088)
- Prostate cancer (DOID:10283)
- CD59 glycoprotein / Homo sapiens
- TAVNCSSDFDACLITK (16aa)
- TAVNCSSDFDACLITK (16aa)
-
- Hex:5 HexNAc:4 NeuAc:1 / N-Linked (avg mass : 1932.7652)
- Reanalysis of global proteomic and phosphoproteomic data identified a large number of glycopeptides (2018 - Yingwei Hu, Punit Shah, David J. Clark, Minghui Ao, Hui Zhang) / Status : Unreviewed
- Distinct urinary glycoprotein signatures in prostate cancer patients (2018 - Rebeca Kawahara, Fabio Ortega, Livia Rosa-Fernandes, Vanessa Guimarães, Daniel Quina, Willian Nahas, Veit Schwämmle, Miguel Srougi, Katia R.M. Leite, Morten Thaysen-Andersen, Martin R. Larsen and Giuseppe Palmisano) / Status : Unreviewed
- CD59 glycoprotein / Homo sapiens
- TAVNCSSDFDACLITK (16aa)
- TAVNCSSDFDACLITK (16aa)
- TAVNCSSDFDACIITK (16aa)
-
- Hex:5 HexNAc:4 dHex:2 / N-Linked (avg mass : 1933.7933)
- Urine (UBERON_0001088)
- Prostate cancer (DOID:10283)
- CD59 glycoprotein / Homo sapiens
- TAVNCSSDFDACLITK (16aa)
- TAVNCSSDFDACLITK (16aa)
-
- Hex:6 HexNAc:4 dHex:1 / N-Linked (avg mass : 1949.7927)
- Urine (UBERON_0001088)
- Prostate cancer (DOID:10283)
- CD59 glycoprotein / Homo sapiens
- TAVNCSSDFDACLITK (16aa)
- TAVNCSSDFDACLITK (16aa)
-
- Hex:4 HexNAc:5 NeuAc:1 / N-Linked (avg mass : 1973.8178)
- CD59 glycoprotein / Homo sapiens
-
- Hex:5 HexNAc:5 dHex:1 / N-Linked (avg mass : 1990.8453)
- Urine (UBERON_0001088)
- Prostate cancer (DOID:10283)
- CD59 glycoprotein / Homo sapiens
- TAVNCSSDFDACLITK (16aa)
- TAVNCSSDFDACLITK (16aa)
-
- Hex:6 HexNAc:3 dHex:3 / N-Linked (avg mass : 2038.8837)
- Mammary Gland (UBERON_0001911)
- Cancer, breast (DOID:1612)
- CD59 glycoprotein / Homo sapiens
- TAVNCSSDFDACIITK (16aa)
-
- Hex:10 HexNAc:2 / N-Linked (avg mass : 2045.8293)
- Urine (UBERON_0001088)
- Prostate cancer (DOID:10283)
- CD59 glycoprotein / Homo sapiens
- TAVNCSSDFDACLITK (16aa)
- TAVNCSSDFDACLITK (16aa)
-
- Hex:5 HexNAc:4 dHex:1 NeuAc:1 / N-Linked (avg mass : 2078.9082)
- Reanalysis of global proteomic and phosphoproteomic data identified a large number of glycopeptides (2018 - Yingwei Hu, Punit Shah, David J. Clark, Minghui Ao, Hui Zhang) / Status : Unreviewed
- Distinct urinary glycoprotein signatures in prostate cancer patients (2018 - Rebeca Kawahara, Fabio Ortega, Livia Rosa-Fernandes, Vanessa Guimarães, Daniel Quina, Willian Nahas, Veit Schwämmle, Miguel Srougi, Katia R.M. Leite, Morten Thaysen-Andersen, Martin R. Larsen and Giuseppe Palmisano) / Status : Unreviewed
- CD59 glycoprotein / Homo sapiens
- TAVNCSSDFDACLITK (16aa)
- TAVNCSSDFDACLITK (16aa)
- TAVNCSSDFDACIITK (16aa)
-
- Hex:6 HexNAc:4 NeuAc:1 / N-Linked (avg mass : 2094.9076)
- Urine (UBERON_0001088)
- Prostate cancer (DOID:10283)
- CD59 glycoprotein / Homo sapiens
- TAVNCSSDFDACLITK (16aa)
- TAVNCSSDFDACLITK (16aa)
-
- Hex:6 HexNAc:4 dHex:2 / N-Linked (avg mass : 2095.9357)
- Urine (UBERON_0001088)
- Prostate cancer (DOID:10283)
- CD59 glycoprotein / Homo sapiens
- TAVNCSSDFDACLITK (16aa)
- TAVNCSSDFDACLITK (16aa)
-
- Hex:7 HexNAc:4 dHex:1 / N-Linked (avg mass : 2111.9351)
- Urine (UBERON_0001088)
- Prostate cancer (DOID:10283)
- CD59 glycoprotein / Homo sapiens
- TAVNCSSDFDACLITK (16aa)
- TAVNCSSDFDACLITK (16aa)
-
- Hex:4 HexNAc:5 dHex:1 NeuAc:1 / N-Linked (avg mass : 2119.9608)
- Urine (UBERON_0001088)
- Prostate cancer (DOID:10283)
- CD59 glycoprotein / Homo sapiens
- TAVNCSSDFDACLITK (16aa)
- TAVNCSSDFDACLITK (16aa)
-
- Hex:5 HexNAc:5 NeuAc:1 / N-Linked (avg mass : 2135.9602)
- Urine (UBERON_0001088)
- Prostate cancer (DOID:10283)
- CD59 glycoprotein / Homo sapiens
- TAVNCSSDFDACLITK (16aa)
- TAVNCSSDFDACLITK (16aa)
-
- Hex:5 HexNAc:5 dHex:2 / N-Linked (avg mass : 2136.9883)
- Urine (UBERON_0001088)
- Prostate cancer (DOID:10283)
- CD59 glycoprotein / Homo sapiens
- TAVNCSSDFDACLITK (16aa)
- TAVNCSSDFDACLITK (16aa)
-
- Hex:6 HexNAc:5 dHex:1 / N-Linked (avg mass : 2152.9877)
- Urine (UBERON_0001088)
- Prostate cancer (DOID:10283)
- CD59 glycoprotein / Homo sapiens
- TAVNCSSDFDACLITK (16aa)
- TAVNCSSDFDACLITK (16aa)
-
- Hex:5 HexNAc:4 NeuAc:2 / N-Linked (avg mass : 2224.0231)
- Reanalysis of global proteomic and phosphoproteomic data identified a large number of glycopeptides (2018 - Yingwei Hu, Punit Shah, David J. Clark, Minghui Ao, Hui Zhang) / Status : Unreviewed
- Distinct urinary glycoprotein signatures in prostate cancer patients (2018 - Rebeca Kawahara, Fabio Ortega, Livia Rosa-Fernandes, Vanessa Guimarães, Daniel Quina, Willian Nahas, Veit Schwämmle, Miguel Srougi, Katia R.M. Leite, Morten Thaysen-Andersen, Martin R. Larsen and Giuseppe Palmisano) / Status : Unreviewed
- CD59 glycoprotein / Homo sapiens
- TAVNCSSDFDACLITK (16aa)
- TAVNCSSDFDACLITK (16aa)
- TAVNCSSDFDACIITK (16aa)
-
- Hex:5 HexNAc:4 dHex:2 NeuAc:1 / N-Linked (avg mass : 2225.0512)
- Reanalysis of global proteomic and phosphoproteomic data identified a large number of glycopeptides (2018 - Yingwei Hu, Punit Shah, David J. Clark, Minghui Ao, Hui Zhang) / Status : Unreviewed
- Distinct urinary glycoprotein signatures in prostate cancer patients (2018 - Rebeca Kawahara, Fabio Ortega, Livia Rosa-Fernandes, Vanessa Guimarães, Daniel Quina, Willian Nahas, Veit Schwämmle, Miguel Srougi, Katia R.M. Leite, Morten Thaysen-Andersen, Martin R. Larsen and Giuseppe Palmisano) / Status : Unreviewed
- CD59 glycoprotein / Homo sapiens
- TAVNCSSDFDACLITK (16aa)
- TAVNCSSDFDACLITK (16aa)
- TAVNCSSDFDACIITK (16aa)
-
- Hex:5 HexNAc:4 dHex:4 / N-Linked (avg mass : 2226.0793)
- Mammary Gland (UBERON_0001911)
- Cancer, breast (DOID:1612)
- CD59 glycoprotein / Homo sapiens
- TAVNCSSDFDACIITK (16aa)
-
- Hex:6 HexNAc:4 dHex:1 NeuAc:1 / N-Linked (avg mass : 2241.0506)
- Reanalysis of global proteomic and phosphoproteomic data identified a large number of glycopeptides (2018 - Yingwei Hu, Punit Shah, David J. Clark, Minghui Ao, Hui Zhang) / Status : Unreviewed
- Distinct urinary glycoprotein signatures in prostate cancer patients (2018 - Rebeca Kawahara, Fabio Ortega, Livia Rosa-Fernandes, Vanessa Guimarães, Daniel Quina, Willian Nahas, Veit Schwämmle, Miguel Srougi, Katia R.M. Leite, Morten Thaysen-Andersen, Martin R. Larsen and Giuseppe Palmisano) / Status : Unreviewed
- CD59 glycoprotein / Homo sapiens
- TAVNCSSDFDACLITK (16aa)
- TAVNCSSDFDACLITK (16aa)
- TAVNCSSDFDACIITK (16aa)
-
- Hex:6 HexNAc:4 dHex:3 / N-Linked (avg mass : 2242.0787)
- Reanalysis of global proteomic and phosphoproteomic data identified a large number of glycopeptides (2018 - Yingwei Hu, Punit Shah, David J. Clark, Minghui Ao, Hui Zhang) / Status : Unreviewed
- Distinct urinary glycoprotein signatures in prostate cancer patients (2018 - Rebeca Kawahara, Fabio Ortega, Livia Rosa-Fernandes, Vanessa Guimarães, Daniel Quina, Willian Nahas, Veit Schwämmle, Miguel Srougi, Katia R.M. Leite, Morten Thaysen-Andersen, Martin R. Larsen and Giuseppe Palmisano) / Status : Unreviewed
- CD59 glycoprotein / Homo sapiens
- TAVNCSSDFDACLITK (16aa)
- TAVNCSSDFDACLITK (16aa)
- TAVNCSSDFDACIITK (16aa)
-
- Hex:7 HexNAc:4 NeuAc:1 / N-Linked (avg mass : 2257.05)
- Urine (UBERON_0001088)
- Prostate cancer (DOID:10283)
- CD59 glycoprotein / Homo sapiens
- TAVNCSSDFDACLITK (16aa)
- TAVNCSSDFDACLITK (16aa)
-
- Hex:7 HexNAc:4 dHex:2 / N-Linked (avg mass : 2258.0781)
- Urine (UBERON_0001088)
- Prostate cancer (DOID:10283)
- CD59 glycoprotein / Homo sapiens
- TAVNCSSDFDACLITK (16aa)
- TAVNCSSDFDACLITK (16aa)
-
- Hex:4 HexNAc:5 dHex:2 NeuAc:1 / N-Linked (avg mass : 2266.1038)
- Mammary Gland (UBERON_0001911)
- Cancer, breast (DOID:1612)
- CD59 glycoprotein / Homo sapiens
- TAVNCSSDFDACIITK (16aa)
-
- Hex:5 HexNAc:5 dHex:1 NeuAc:1 / N-Linked (avg mass : 2282.1032)
- Urine (UBERON_0001088)
- Prostate cancer (DOID:10283)
- CD59 glycoprotein / Homo sapiens
- TAVNCSSDFDACLITK (16aa)
- TAVNCSSDFDACLITK (16aa)
-
- Hex:5 HexNAc:5 dHex:3 / N-Linked (avg mass : 2283.1313)
- Urine (UBERON_0001088)
- Prostate cancer (DOID:10283)
- CD59 glycoprotein / Homo sapiens
- TAVNCSSDFDACLITK (16aa)
- TAVNCSSDFDACLITK (16aa)
-
- Hex:6 HexNAc:5 NeuAc:1 / N-Linked (avg mass : 2298.1026)
- Urine (UBERON_0001088)
- Prostate cancer (DOID:10283)
- CD59 glycoprotein / Homo sapiens
- TAVNCSSDFDACLITK (16aa)
- TAVNCSSDFDACLITK (16aa)
-
- Hex:7 HexNAc:5 dHex:1 / N-Linked (avg mass : 2315.1301)
- Urine (UBERON_0001088)
- Prostate cancer (DOID:10283)
- CD59 glycoprotein / Homo sapiens
- TAVNCSSDFDACLITK (16aa)
- TAVNCSSDFDACLITK (16aa)
-
- Hex:12 HexNAc:2 / N-Linked (avg mass : 2370.1141)
- Mammary Gland (UBERON_0001911)
- Cancer, breast (DOID:1612)
- CD59 glycoprotein / Homo sapiens
- TAVNCSSDFDACIITK (16aa)
-
- Hex:5 HexNAc:4 dHex:1 NeuAc:2 / N-Linked (avg mass : 2370.1661)
- Reanalysis of global proteomic and phosphoproteomic data identified a large number of glycopeptides (2018 - Yingwei Hu, Punit Shah, David J. Clark, Minghui Ao, Hui Zhang) / Status : Unreviewed
- Distinct urinary glycoprotein signatures in prostate cancer patients (2018 - Rebeca Kawahara, Fabio Ortega, Livia Rosa-Fernandes, Vanessa Guimarães, Daniel Quina, Willian Nahas, Veit Schwämmle, Miguel Srougi, Katia R.M. Leite, Morten Thaysen-Andersen, Martin R. Larsen and Giuseppe Palmisano) / Status : Unreviewed
- CD59 glycoprotein / Homo sapiens
- TAVNCSSDFDACLITK (16aa)
- TAVNCSSDFDACLITK (16aa)
- TAVNCSSDFDACIITK (16aa)
-
- Hex:5 HexNAc:4 dHex:3 NeuAc:1 / N-Linked (avg mass : 2371.1942)
- Urine (UBERON_0001088)
- Prostate cancer (DOID:10283)
- CD59 glycoprotein / Homo sapiens
- TAVNCSSDFDACLITK (16aa)
- TAVNCSSDFDACLITK (16aa)
-
- Hex:7 HexNAc:6 / N-Linked (avg mass : 2372.1821)
- Mammary Gland (UBERON_0001911)
- Cancer, breast (DOID:1612)
- CD59 glycoprotein / Homo sapiens
- TAVNCSSDFDACIITK (16aa)
-
- Hex:4 HexNAc:7 dHex:2 / N-Linked (avg mass : 2381.2359)
- Urine (UBERON_0001088)
- Prostate cancer (DOID:10283)
- CD59 glycoprotein / Homo sapiens
- TAVNCSSDFDACLITK (16aa)
- TAVNCSSDFDACLITK (16aa)
-
- Hex:5 HexNAc:4 dHex:1 NeuAc:1 NeuGc:1 / N-Linked (avg mass : 2386.1655)
- Urine (UBERON_0001088)
- Prostate cancer (DOID:10283)
- CD59 glycoprotein / Homo sapiens
- TAVNCSSDFDACLITK (16aa)
- TAVNCSSDFDACLITK (16aa)
-
- Hex:5 HexNAc:4 dHex:1 NeuGc:2 / N-Linked (avg mass : 2402.1649)
- Urine (UBERON_0001088)
- Prostate cancer (DOID:10283)
- CD59 glycoprotein / Homo sapiens
- TAVNCSSDFDACLITK (16aa)
- TAVNCSSDFDACLITK (16aa)
-
- Hex:4 HexNAc:5 dHex:1 NeuAc:2 / N-Linked (avg mass : 2411.2187)
- Urine (UBERON_0001088)
- Prostate cancer (DOID:10283)
- CD59 glycoprotein / Homo sapiens
- TAVNCSSDFDACLITK (16aa)
- TAVNCSSDFDACLITK (16aa)
-
- Hex:6 HexNAc:7 / N-Linked (avg mass : 2413.2347)
- Urine (UBERON_0001088)
- Prostate cancer (DOID:10283)
- CD59 glycoprotein / Homo sapiens
- TAVNCSSDFDACLITK (16aa)
- TAVNCSSDFDACLITK (16aa)
-
- Hex:4 HexNAc:5 dHex:1 NeuAc:1 NeuGc:1 / N-Linked (avg mass : 2427.2181)
- Urine (UBERON_0001088)
- Prostate cancer (DOID:10283)
- CD59 glycoprotein / Homo sapiens
- TAVNCSSDFDACLITK (16aa)
- TAVNCSSDFDACLITK (16aa)
-
- Hex:5 HexNAc:5 dHex:2 NeuAc:1 / N-Linked (avg mass : 2428.2462)
- Mammary Gland (UBERON_0001911)
- Cancer, breast (DOID:1612)
- CD59 glycoprotein / Homo sapiens
- TAVNCSSDFDACIITK (16aa)
-
- Hex:6 HexNAc:5 dHex:1 NeuAc:1 / N-Linked (avg mass : 2444.2456)
- Reanalysis of global proteomic and phosphoproteomic data identified a large number of glycopeptides (2018 - Yingwei Hu, Punit Shah, David J. Clark, Minghui Ao, Hui Zhang) / Status : Unreviewed
- Distinct urinary glycoprotein signatures in prostate cancer patients (2018 - Rebeca Kawahara, Fabio Ortega, Livia Rosa-Fernandes, Vanessa Guimarães, Daniel Quina, Willian Nahas, Veit Schwämmle, Miguel Srougi, Katia R.M. Leite, Morten Thaysen-Andersen, Martin R. Larsen and Giuseppe Palmisano) / Status : Unreviewed
- CD59 glycoprotein / Homo sapiens
- TAVNCSSDFDACLITK (16aa)
- TAVNCSSDFDACLITK (16aa)
- TAVNCSSDFDACIITK (16aa)
-
- Hex:6 HexNAc:5 dHex:1 NeuGc:1 / N-Linked (avg mass : 2460.245)
- Urine (UBERON_0001088)
- Prostate cancer (DOID:10283)
- CD59 glycoprotein / Homo sapiens
- TAVNCSSDFDACLITK (16aa)
- TAVNCSSDFDACLITK (16aa)
-
- Hex:3 HexNAc:6 dHex:1 NeuAc:1 NeuGc:1 / N-Linked (avg mass : 2468.2707)
- Urine (UBERON_0001088)
- Prostate cancer (DOID:10283)
- CD59 glycoprotein / Homo sapiens
- TAVNCSSDFDACLITK (16aa)
- TAVNCSSDFDACLITK (16aa)
-
- Hex:3 HexNAc:9 dHex:1 / N-Linked (avg mass : 2479.3405)
- Urine (UBERON_0001088)
- Prostate cancer (DOID:10283)
- CD59 glycoprotein / Homo sapiens
- TAVNCSSDFDACLITK (16aa)
- TAVNCSSDFDACLITK (16aa)
-
- Hex:5 HexNAc:6 dHex:1 NeuAc:1 / N-Linked (avg mass : 2485.2982)
- Urine (UBERON_0001088)
- Prostate cancer (DOID:10283)
- CD59 glycoprotein / Homo sapiens
- TAVNCSSDFDACLITK (16aa)
- TAVNCSSDFDACLITK (16aa)
-
- Hex:6 HexNAc:6 NeuAc:1 / N-Linked (avg mass : 2501.2976)
- Urine (UBERON_0001088)
- Prostate cancer (DOID:10283)
- CD59 glycoprotein / Homo sapiens
- TAVNCSSDFDACLITK (16aa)
- TAVNCSSDFDACLITK (16aa)
-
- Hex:6 HexNAc:6 dHex:2 / N-Linked (avg mass : 2502.3257)
- Urine (UBERON_0001088)
- Prostate cancer (DOID:10283)
- CD59 glycoprotein / Homo sapiens
- TAVNCSSDFDACLITK (16aa)
- TAVNCSSDFDACLITK (16aa)
-
- Hex:5 HexNAc:5 dHex:1 NeuAc:2 / N-Linked (avg mass : 2573.3611)
- Reanalysis of global proteomic and phosphoproteomic data identified a large number of glycopeptides (2018 - Yingwei Hu, Punit Shah, David J. Clark, Minghui Ao, Hui Zhang) / Status : Unreviewed
- Distinct urinary glycoprotein signatures in prostate cancer patients (2018 - Rebeca Kawahara, Fabio Ortega, Livia Rosa-Fernandes, Vanessa Guimarães, Daniel Quina, Willian Nahas, Veit Schwämmle, Miguel Srougi, Katia R.M. Leite, Morten Thaysen-Andersen, Martin R. Larsen and Giuseppe Palmisano) / Status : Unreviewed
- CD59 glycoprotein / Homo sapiens
- TAVNCSSDFDACLITK (16aa)
- TAVNCSSDFDACLITK (16aa)
- TAVNCSSDFDACIITK (16aa)
-
- Hex:6 HexNAc:5 dHex:2 NeuAc:1 / N-Linked (avg mass : 2590.3886)
- Urine (UBERON_0001088)
- Prostate cancer (DOID:10283)
- CD59 glycoprotein / Homo sapiens
- TAVNCSSDFDACLITK (16aa)
- TAVNCSSDFDACLITK (16aa)
-
- Hex:5 HexNAc:8 dHex:1 / N-Linked (avg mass : 2600.4303)
- Urine (UBERON_0001088)
- Prostate cancer (DOID:10283)
- CD59 glycoprotein / Homo sapiens
- TAVNCSSDFDACLITK (16aa)
- TAVNCSSDFDACLITK (16aa)
-
- Hex:7 HexNAc:5 dHex:1 NeuAc:1 / N-Linked (avg mass : 2606.388)
- Urine (UBERON_0001088)
- Prostate cancer (DOID:10283)
- CD59 glycoprotein / Homo sapiens
- TAVNCSSDFDACLITK (16aa)
- TAVNCSSDFDACLITK (16aa)
-
- Hex:6 HexNAc:8 / N-Linked (avg mass : 2616.4297)
- Urine (UBERON_0001088)
- Prostate cancer (DOID:10283)
- CD59 glycoprotein / Homo sapiens
- TAVNCSSDFDACLITK (16aa)
- TAVNCSSDFDACLITK (16aa)
-
- Hex:4 HexNAc:9 dHex:1 / N-Linked (avg mass : 2641.4829)
- Urine (UBERON_0001088)
- Prostate cancer (DOID:10283)
- CD59 glycoprotein / Homo sapiens
- TAVNCSSDFDACLITK (16aa)
- TAVNCSSDFDACLITK (16aa)
-
- Hex:6 HexNAc:6 dHex:1 NeuAc:1 / N-Linked (avg mass : 2647.4406)
- Urine (UBERON_0001088)
- Prostate cancer (DOID:10283)
- CD59 glycoprotein / Homo sapiens
- TAVNCSSDFDACLITK (16aa)
- TAVNCSSDFDACLITK (16aa)
-
- Hex:5 HexNAc:4 dHex:3 NeuAc:2 / N-Linked (avg mass : 2662.4521)
- Urine (UBERON_0001088)
- Prostate cancer (DOID:10283)
- CD59 glycoprotein / Homo sapiens
- TAVNCSSDFDACLITK (16aa)
- TAVNCSSDFDACLITK (16aa)
-
- Hex:5 HexNAc:4 dHex:3 NeuAc:1 NeuGc:1 / N-Linked (avg mass : 2678.4515)
- Urine (UBERON_0001088)
- Prostate cancer (DOID:10283)
- CD59 glycoprotein / Homo sapiens
- TAVNCSSDFDACLITK (16aa)
- TAVNCSSDFDACLITK (16aa)
-
- Hex:7 HexNAc:6 NeuGc:1 / N-Linked (avg mass : 2679.4394)
- Urine (UBERON_0001088)
- Prostate cancer (DOID:10283)
- CD59 glycoprotein / Homo sapiens
- TAVNCSSDFDACLITK (16aa)
- TAVNCSSDFDACLITK (16aa)
-
- Hex:5 HexNAc:4 dHex:3 NeuGc:2 / N-Linked (avg mass : 2694.4509)
- Urine (UBERON_0001088)
- Prostate cancer (DOID:10283)
- CD59 glycoprotein / Homo sapiens
- TAVNCSSDFDACLITK (16aa)
- TAVNCSSDFDACLITK (16aa)
-
- Hex:9 HexNAc:6 / N-Linked (avg mass : 2696.4669)
- Urine (UBERON_0001088)
- Prostate cancer (DOID:10283)
- CD59 glycoprotein / Homo sapiens
- TAVNCSSDFDACLITK (16aa)
- TAVNCSSDFDACLITK (16aa)
-
- Hex:7 HexNAc:7 dHex:1 / N-Linked (avg mass : 2721.5201)
- Urine (UBERON_0001088)
- Prostate cancer (DOID:10283)
- CD59 glycoprotein / Homo sapiens
- TAVNCSSDFDACLITK (16aa)
- TAVNCSSDFDACLITK (16aa)
-
- Hex:6 HexNAc:5 dHex:1 NeuAc:2 / N-Linked (avg mass : 2735.5035)
- Reanalysis of global proteomic and phosphoproteomic data identified a large number of glycopeptides (2018 - Yingwei Hu, Punit Shah, David J. Clark, Minghui Ao, Hui Zhang) / Status : Unreviewed
- Distinct urinary glycoprotein signatures in prostate cancer patients (2018 - Rebeca Kawahara, Fabio Ortega, Livia Rosa-Fernandes, Vanessa Guimarães, Daniel Quina, Willian Nahas, Veit Schwämmle, Miguel Srougi, Katia R.M. Leite, Morten Thaysen-Andersen, Martin R. Larsen and Giuseppe Palmisano) / Status : Unreviewed
- CD59 glycoprotein / Homo sapiens
- TAVNCSSDFDACLITK (16aa)
- TAVNCSSDFDACLITK (16aa)
- TAVNCSSDFDACIITK (16aa)
-
- Hex:6 HexNAc:5 dHex:3 NeuAc:1 / N-Linked (avg mass : 2736.5316)
- Reanalysis of global proteomic and phosphoproteomic data identified a large number of glycopeptides (2018 - Yingwei Hu, Punit Shah, David J. Clark, Minghui Ao, Hui Zhang) / Status : Unreviewed
- Distinct urinary glycoprotein signatures in prostate cancer patients (2018 - Rebeca Kawahara, Fabio Ortega, Livia Rosa-Fernandes, Vanessa Guimarães, Daniel Quina, Willian Nahas, Veit Schwämmle, Miguel Srougi, Katia R.M. Leite, Morten Thaysen-Andersen, Martin R. Larsen and Giuseppe Palmisano) / Status : Unreviewed
- CD59 glycoprotein / Homo sapiens
- TAVNCSSDFDACLITK (16aa)
- TAVNCSSDFDACLITK (16aa)
- TAVNCSSDFDACIITK (16aa)
-
- Hex:6 HexNAc:5 dHex:1 NeuAc:1 NeuGc:1 / N-Linked (avg mass : 2751.5029)
- Urine (UBERON_0001088)
- Prostate cancer (DOID:10283)
- CD59 glycoprotein / Homo sapiens
- TAVNCSSDFDACLITK (16aa)
- TAVNCSSDFDACLITK (16aa)
-
- Hex:6 HexNAc:5 dHex:3 NeuGc:1 / N-Linked (avg mass : 2752.531)
- Urine (UBERON_0001088)
- Prostate cancer (DOID:10283)
-
CD59 glycoprotein / Homo sapiens
Source
Suggested structure
Disease
Reported glycosite
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Suggested structure
Reference
Reported glycosite
Mass spectrometry observed peptide
Suggested structure
Reference
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Suggested structure
Reference
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Suggested structure
Reference
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Suggested structure
Reference
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Suggested structure
Reference
Reported glycosite
Mass spectrometry observed peptide
Suggested structure
Reference
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Suggested structure
Reference
Reported glycosite
Mass spectrometry observed peptide
Suggested structure
Reference
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Suggested structure
Reference
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Suggested structure
Reference
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Disease
Reported glycosite
Suggested glycosite
Source
Disease
Reported glycosite
Suggested glycosite
Source
Disease
Reported glycosite
Suggested glycosite
Source
Disease
Reported glycosite
Suggested glycosite
Source
Disease
Reported glycosite
Suggested glycosite
Source
Disease
Reported glycosite
Suggested glycosite
Disease
Reference
Reported glycosite
Suggested glycosite
Source
Disease
Reported glycosite
Suggested glycosite
Source
Disease
Reported glycosite
Suggested glycosite
Source
Disease
Reported glycosite
Suggested glycosite